Algeria / 103,833+ cases
Russia’s Sputnik-V vaccine has been ordered. The country also expects to receive a batch of vaccinations from China before the end of January.
Bahrain / 97,607+ cases
Vaccines from China’s Sinopharm and the US/German Pfizer-BioNTech are in use. A January batch of the latter jab was delayed, but this did not affect the administration of second doses as scheduled.
Egypt / 156,397+ cases
Frontline medical workers are receiving the Sinopharm vaccine. Vaccine alliance Gavi will provide 20 million vaccine doses to Cairo. The government plans to secure 20 per cent of vaccine needs from Gavi and 30 per cent through the Oxford University-AstraZeneca jab.
Iran / 1,336,217+ cases
Central Bank chief Abdulnaser Hemmati has said $243.5m has been set aside to purchase vaccines. The Iranian Red Crescent’s head, Karim Hemmati, said donors had provided 150,000 doses of the Pfizer-BioNTech jab.
Iraq / 608,232+ cases
Pfizer-BioNTech, Sinopharm and Oxford-AstraZeneca vaccines have been approved for use in Iraq. The country is expecting 1.5 million doses of the Pfizer-BioNTech vaccine.
Jordan / 314,514+ cases
The Johnson & Johnson (US), Pfizer-BioNTech, Sinopharm and Oxford-AstraZeneca vaccines are approved for use. A widespread inoculation programme is under way in the country.
Kuwait / 157,777+ cases
Pfizer-BioNTech jabs are in use in the country, with the Oxford-AstraZeneca vaccine also planned for use in the future. Kuwait aims to vaccinate 80 per cent of its population by September.
Lebanon / 252,812+ cases
An agreement has been confirmed for the Pfizer-BioNTech vaccine to be used in Lebanon. The country is also eyeing confirmations for the Sinopharm and Oxford-AstraZeneca jabs to be used.
Libya / 109,869+ cases
Libya is part of the Covax facility co-led by Gavi, Coalition for Epidemic Preparedness Innovations and the WHO. About $9.6m was allocated for vaccine procurement in November.
Morocco / 459,671+ cases
The Sinopharm and Oxford-AstraZeneca jabs are approved for use and the inoculation campaign will target 25 million people who will be vaccinated free of charge.
Oman / 132,011+ cases
The Pfizer-BioNTech vaccine is in use. Oman is aiming for 82 per cent vaccine coverage in key groups such as high-risk individuals and frontline workers.
Qatar / 147,277+ cases
The government has said that the Pfizer-BioNTech vaccine will be procured and prioritised for the elderly, frontline workers and people with chronic illnesses.
Saudi Arabia / 364,929+ cases
The Pfizer-BioNTech is in use and the Oxford-AstraZeneca and Moderna vaccines have been approved. Global demand for the Pfizer-BioNTech jabs could lead administration timelines to be rescheduled.
Syria / 13,036+ cases
Negotiations are under way to procure the Russian Sputnik-V vaccine. Foreign Minister Faisal Mekdad has said he is hopeful that Damascus will receive the vaccine for free.
Tunisia / 180,090+ cases
The Pfizer-BioNTech and Sputnik-V vaccines have been confirmed for use, with delivery of the latter awaited as of mid-January. Tunis has allocated at least $100m for the procurement of vaccines.
UAE / 256,732+ cases
The Sinopharm, Pfizer-BioNTech and Sputnik-V vaccines have been confirmed for use, with more than 2 million doses of the Chinese and US/German jabs having already been administered.
You might also like...
A MEED Subscription...
Subscribe or upgrade your current MEED.com package to support your strategic planning with the MENA region’s best source of business information. Proceed to our online shop below to find out more about the features in each package.